ES2100046T3 - Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro. - Google Patents

Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.

Info

Publication number
ES2100046T3
ES2100046T3 ES94904855T ES94904855T ES2100046T3 ES 2100046 T3 ES2100046 T3 ES 2100046T3 ES 94904855 T ES94904855 T ES 94904855T ES 94904855 T ES94904855 T ES 94904855T ES 2100046 T3 ES2100046 T3 ES 2100046T3
Authority
ES
Spain
Prior art keywords
pain
optically pure
ketorolac
antipiretic
ketorolaco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94904855T
Other languages
English (en)
Inventor
Timothy J Barberich
Stephen L Matson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ES2100046T3 publication Critical patent/ES2100046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICION FARMACEUTICA QUE CONTIENE R-KETOROLAC, SUSTANCIALMENTE LIBRE DE S ESTEROISOMERO, PARA USO EN TRATAMIENTOS ANALGESICOS Y ANTIPIRETICOS, QUE NO PRODUCE EFECTOS SECUNDARIOS SIGNIFICATIVAMENTE ADVERSOS ASOCIADOS A LA ADMINISTRACION DE KETOROLAC RACEMICO, INCLUYENDO LA ADMINISTRACION DE CANTIDADES DE R-KETOROLAC TERAPEUTICAMENTE EFECTIVAS PARA PACIENTES HUMANOS.
ES94904855T 1992-12-17 1993-12-17 Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro. Expired - Lifetime ES2100046T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99198192A 1992-12-17 1992-12-17

Publications (1)

Publication Number Publication Date
ES2100046T3 true ES2100046T3 (es) 1997-06-01

Family

ID=25537797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94904855T Expired - Lifetime ES2100046T3 (es) 1992-12-17 1993-12-17 Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.

Country Status (14)

Country Link
US (1) US5382591A (es)
EP (1) EP0674511B1 (es)
JP (1) JP2957701B2 (es)
KR (1) KR100264814B1 (es)
AT (1) ATE150969T1 (es)
AU (1) AU696620B2 (es)
CA (1) CA2151724C (es)
DE (1) DE69309492T2 (es)
DK (1) DK0674511T3 (es)
ES (1) ES2100046T3 (es)
FI (1) FI952985A (es)
GR (1) GR3023741T3 (es)
NO (1) NO307546B1 (es)
WO (1) WO1994013283A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
ES2253810T3 (es) * 1997-03-10 2006-06-01 Loma Linda University Medical Center Uso de r-aines para la prevencion de la enfermedad de alzheimer.
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6576191B1 (en) * 1999-09-30 2003-06-10 Therox, Inc. Apparatus for blood oxygenation
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
AU2003211009A1 (en) * 2002-02-11 2003-09-04 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
MX2008003230A (es) * 2008-03-07 2009-09-07 Senosiain S A De C V Lab Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
CN112094271B (zh) * 2019-06-18 2023-03-21 鲁南制药集团股份有限公司 一种酮咯酸晶型及其制备方法
CN110540542A (zh) * 2019-09-12 2019-12-06 南京海融制药有限公司 一种苯乙酸类化合物的钠盐、结晶形式及其制备方法
EP4110329A4 (en) * 2020-02-24 2024-04-10 Yinuoke Medicine Science Technology Company Ltd. COMPOSITIONS AND METHODS FOR TREATING CYTOKINE STORM AND CYTOKINE RELEASE SYNDROME
CN114276350B (zh) * 2020-09-28 2023-05-16 鲁南制药集团股份有限公司 一种酮咯酸与吩嗪共晶及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
WO1987006266A1 (en) * 1986-04-16 1987-10-22 Wisconsin Alumni Research Foundation ENZYMATIC PROCESS FOR PREPARING OPTICALLY-ACTIVE 1,2-DIHYDRO-3H-PYRROLO[1,2a]PYRROLE-1-CARBOXYLIC ACID DERIVATIVES
ES2086536T3 (es) * 1990-03-16 1996-07-01 Procter & Gamble Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
JP3541849B2 (ja) * 1991-04-19 2004-07-14 久光製薬株式会社 消炎鎮痛貼付剤
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac

Also Published As

Publication number Publication date
WO1994013283A1 (en) 1994-06-23
CA2151724C (en) 2000-10-31
DE69309492T2 (de) 1997-07-10
NO952418L (no) 1995-08-03
NO952418D0 (no) 1995-06-16
EP0674511B1 (en) 1997-04-02
GR3023741T3 (en) 1997-09-30
US5382591A (en) 1995-01-17
KR100264814B1 (ko) 2000-09-01
NO307546B1 (no) 2000-04-25
FI952985A0 (fi) 1995-06-16
ATE150969T1 (de) 1997-04-15
JP2957701B2 (ja) 1999-10-06
AU696620B2 (en) 1998-09-17
DE69309492D1 (de) 1997-05-07
FI952985A (fi) 1995-08-16
JPH08505133A (ja) 1996-06-04
EP0674511A1 (en) 1995-10-04
KR950703951A (ko) 1995-11-17
CA2151724A1 (en) 1994-06-23
DK0674511T3 (da) 1997-04-21
AU5872194A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
ES2100046T3 (es) Composiciones antipireticas y analgesicas que contienen r-ketorolaco opticamente puro.
EP0727994A4 (en) ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE ETODOLIC ACID
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
RU94042899A (ru) Способ достижения болеутоляющего эффекта, способ лечения и профилактики гипертермии у человека, болеутоляющая и жаропонижающая композиции, содержащие оптически чистый r (-) кетопрофен
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
EP1022025A3 (en) Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
FI973163A (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
HUP9904360A2 (hu) Eljárás emesis és központi idegrendszeri rendellenességek kezelésére, optikailag tiszta (+)-norciszaprid alkalmazásával
ATE189601T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
SE9404080D0 (sv) Förfarande för framställning av en optiskt ren enantiomer av formoterol
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
HUP0000873A2 (hu) A levobupivakain arcsebészeti alkalmazása
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
DE68927519D1 (de) Behandlung von erhöhtem Blutdruck
MY114716A (en) Prophylactic and/or therapeutic treatment of dyspeptic symptoms
DK0744951T3 (da) Fremgangsmåde til fremstilling af en steril prednisolongen
DK0769945T3 (da) Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674511

Country of ref document: ES